IRIS Accounts Production v25.1.4.42 02541650 Board of Directors 1.10.23 30.9.24 30.9.24 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh025416502023-09-30025416502024-09-30025416502023-10-012024-09-30025416502022-09-30025416502022-10-012023-09-30025416502023-09-3002541650ns15:EnglandWales2023-10-012024-09-3002541650ns14:PoundSterling2023-10-012024-09-3002541650ns10:Director12023-10-012024-09-3002541650ns10:PrivateLimitedCompanyLtd2023-10-012024-09-3002541650ns10:SmallEntities2023-10-012024-09-3002541650ns10:AuditExempt-NoAccountantsReport2023-10-012024-09-3002541650ns10:SmallCompaniesRegimeForDirectorsReport2023-10-012024-09-3002541650ns10:SmallCompaniesRegimeForAccounts2023-10-012024-09-3002541650ns10:FullAccounts2023-10-012024-09-300254165012023-10-012024-09-3002541650ns10:Director22023-10-012024-09-3002541650ns10:CompanySecretary12023-10-012024-09-3002541650ns10:RegisteredOffice2023-10-012024-09-3002541650ns5:CurrentFinancialInstruments2024-09-3002541650ns5:CurrentFinancialInstruments2023-09-3002541650ns5:ShareCapital2024-09-3002541650ns5:ShareCapital2023-09-3002541650ns5:RetainedEarningsAccumulatedLosses2024-09-3002541650ns5:RetainedEarningsAccumulatedLosses2023-09-3002541650ns5:NetGoodwill2023-10-012024-09-3002541650ns5:IntangibleAssetsOtherThanGoodwill2023-10-012024-09-3002541650ns5:LeaseholdImprovements2023-10-012024-09-3002541650ns5:FurnitureFittings2023-10-012024-09-3002541650ns5:ComputerEquipment2023-10-012024-09-3002541650ns5:NetGoodwill2023-09-3002541650ns5:NetGoodwill2024-09-3002541650ns5:NetGoodwill2023-09-3002541650ns5:LeaseholdImprovements2023-09-3002541650ns5:FurnitureFittings2023-09-3002541650ns5:ComputerEquipment2023-09-3002541650ns5:LeaseholdImprovements2024-09-3002541650ns5:FurnitureFittings2024-09-3002541650ns5:ComputerEquipment2024-09-3002541650ns5:LeaseholdImprovements2023-09-3002541650ns5:FurnitureFittings2023-09-3002541650ns5:ComputerEquipment2023-09-3002541650ns5:WithinOneYearns5:CurrentFinancialInstruments2024-09-3002541650ns5:WithinOneYearns5:CurrentFinancialInstruments2023-09-30
REGISTERED NUMBER: 02541650 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 SEPTEMBER 2024

FOR

GRAHAM JONES PHARMACY LIMITED

GRAHAM JONES PHARMACY LIMITED (REGISTERED NUMBER: 02541650)






CONTENTS OF THE FINANCIAL STATEMENTS
for the year ended 30 SEPTEMBER 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


GRAHAM JONES PHARMACY LIMITED

COMPANY INFORMATION
for the year ended 30 SEPTEMBER 2024







DIRECTORS: Mrs. J.E. Jones
Mr. A.G.B. Jones





SECRETARY: Mrs. J.E. Jones





REGISTERED OFFICE: Graham Jones Pharmacy Limited
7 Court Road
Letcombe Regis
Wantage
Oxfordshire
OX129JH





REGISTERED NUMBER: 02541650 (England and Wales)





ACCOUNTANTS: C B Heslop & Company Limited
Chartered Accountants
1 High Street
Thatcham
Berks
RG19 3JG

GRAHAM JONES PHARMACY LIMITED (REGISTERED NUMBER: 02541650)

BALANCE SHEET
30 SEPTEMBER 2024

30.9.24 30.9.23
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 100 100
Tangible assets 5 42,678 50,265
42,778 50,365

CURRENT ASSETS
Stocks 6 80,407 68,682
Debtors 7 175,194 208,459
Cash at bank and in hand 101,547 200,547
357,148 477,688
CREDITORS
Amounts falling due within one year 8 306,477 296,761
NET CURRENT ASSETS 50,671 180,927
TOTAL ASSETS LESS CURRENT
LIABILITIES

93,449

231,292

PROVISIONS FOR LIABILITIES 6,935 8,119
NET ASSETS 86,514 223,173

CAPITAL AND RESERVES
Called up share capital 1,000 1,000
Retained earnings 85,514 222,173
SHAREHOLDERS' FUNDS 86,514 223,173

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 September 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 September 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

GRAHAM JONES PHARMACY LIMITED (REGISTERED NUMBER: 02541650)

BALANCE SHEET - continued
30 SEPTEMBER 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 11 June 2025 and were signed on its behalf by:





Mr. A.G.B. Jones - Director


GRAHAM JONES PHARMACY LIMITED (REGISTERED NUMBER: 02541650)

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 30 SEPTEMBER 2024

1. STATUTORY INFORMATION

Graham Jones Pharmacy Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill has been written down to a nominal value of £100.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Improvements to property - 15% on reducing balance
Fixtures and fittings - 15% on reducing balance
Office equipment - 25% on reducing balance

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

GRAHAM JONES PHARMACY LIMITED (REGISTERED NUMBER: 02541650)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 30 SEPTEMBER 2024

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 14 (2023 - 14 ) .

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 October 2023
and 30 September 2024 175,700
AMORTISATION
At 1 October 2023
and 30 September 2024 175,600
NET BOOK VALUE
At 30 September 2024 100
At 30 September 2023 100

5. TANGIBLE FIXED ASSETS
Improvements Fixtures
to and Office
property fittings equipment Totals
£    £    £    £   
COST
At 1 October 2023
and 30 September 2024 46,916 188,435 1,117 236,468
DEPRECIATION
At 1 October 2023 35,056 150,501 646 186,203
Charge for year 1,779 5,690 118 7,587
At 30 September 2024 36,835 156,191 764 193,790
NET BOOK VALUE
At 30 September 2024 10,081 32,244 353 42,678
At 30 September 2023 11,860 37,934 471 50,265

6. STOCKS
30.9.24 30.9.23
£    £   
Stocks 80,407 68,682

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.9.24 30.9.23
£    £   
Trade debtors 132,055 122,352
VAT 43,139 86,107
175,194 208,459

GRAHAM JONES PHARMACY LIMITED (REGISTERED NUMBER: 02541650)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 30 SEPTEMBER 2024

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.9.24 30.9.23
£    £   
Trade creditors 277,877 273,493
Tax - (5,437 )
Social security and other taxes 7,708 8,437
Directors' current accounts 14,767 14,143
Accrued expenses 6,125 6,125
306,477 296,761

9. CONTINGENT LIABILITIES

There were no contingent liabilities at 30th September 2024 or at 30th September 2023.

10. RELATED PARTY DISCLOSURES

During the year ended 30th September 2024 the company paid rent of £24,000 (2023 : £24,000) to Mr A G B Jones, a director of the company.



11. ULTIMATE CONTROLLING PARTY

The directors control the company by virtue of a controlling interest of 100% of the issued ordinary share capital.